CSPC Pharmaceutical’s selective ATM inhibitor SYH-2051 cleared to enter clinic in China for solid tumors
June 13, 2023
CSPC Pharmaceutical Group Ltd. has received clinical trial clearance by China’s National Medical Products Administration (NMPA) for SYH-2051 for solid tumors.
